MISC

2004年11月

Effectiveness of BNCT for recurrent head and neck malignancies

APPLIED RADIATION AND ISOTOPES
  • Kato, I
  • ,
  • K Ono
  • ,
  • Y Sakurai
  • ,
  • M Ohmae
  • ,
  • A Maruhashi
  • ,
  • Y Imahori
  • ,
  • M Kirihata
  • ,
  • M Nakazawa
  • ,
  • Y Yura

61
5
開始ページ
1069
終了ページ
1073
記述言語
英語
掲載種別
DOI
10.1016/j.apradiso.2004.05.059
出版者・発行元
PERGAMON-ELSEVIER SCIENCE LTD

Recurrent head and neck malignancies (HNM) are often radio-/chemo-resistant and show extensive growth, necessitating a wide resection including surrounding tissues. To avoid severe impairment of oro-facial structures and functions, it is necessary to explore new treatments for HNM. Boron neutron capture therapy (BNCT) is tumor-cell targeted radiotherapy that has significant superiority over conventional radiotherapies in principle. We report here, first in the world, six patients with a recurrent HNM who have been treated with BNCT. The BNCT in combination with boronophenylalanine (BPA) and borocaptate sodium (BSH) was performed using the epithermal neutrons with Kyoto University Research Reactor (KUR). The results of BNCT were as follows: (1) (10)B concentration of tumor/normal tissue ratios (T/N ratio) of PET studies were SCC:1.8-4.4, sarcoma:3.1-4.0, parotid tumor:3.5. (2) Relative volume (%) of each tumor to the prior were 6-46%. (3) Remarkable reduction (46-100%) of huge tumor such as 40-675 cm(3) (average: 315 cm(3)), improvement of QOL and very mild side effects were recognized in all cases. These results indicate that BNCT represents a new and promising treatment approach even for a huge or far advanced HNM. (C) 2004 Elsevier Ltd. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.apradiso.2004.05.059
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000223506300060&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.apradiso.2004.05.059
  • ISSN : 0969-8043
  • Web of Science ID : WOS:000223506300060

エクスポート
BibTeX RIS